UroGen Long Term Debt from 2010 to 2025
| URGN Stock | USD 9.36 0.15 1.58% |
Long Term Debt | First Reported 2010-12-31 | Previous Quarter 113.3 M | Current Value 119 M | Quarterly Volatility 51.9 M |
Check UroGen Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among UroGen Pharma's main balance sheet or income statement drivers, such as Depreciation And Amortization of 2.1 M, Interest Expense of 17.8 M or Selling General Administrative of 109.1 M, as well as many indicators such as Price To Sales Ratio of 5.71, Dividend Yield of 0.0 or Days Sales Outstanding of 98.77. UroGen financial statements analysis is a perfect complement when working with UroGen Pharma Valuation or Volatility modules.
UroGen | Long Term Debt |
Latest UroGen Pharma's Long Term Debt Growth Pattern
Below is the plot of the Long Term Debt of UroGen Pharma over the last few years. Long-term debt is a debt that UroGen Pharma has held for over one year. Long-term debt appears on UroGen Pharma balance sheet and also includes long-term leases. The most common forms of long term debt are bonds payable, long-term notes payable, mortgage payable, pension liabilities, and lease liabilities. In the corporate world, long-term debt is generally used to fund big-ticket items, such as machinery, buildings, and land. The total of long-term debt reported on UroGen Pharma balance sheet is the sum of the balances of all categories of long-term debt. It is debt that is not due within the current year and is often considered to be financing activities that are to be repaid over several years. UroGen Pharma's Long Term Debt historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in UroGen Pharma's overall financial position and show how it may be relating to other accounts over time.
| Long Term Debt | 10 Years Trend |
|
Long Term Debt |
| Timeline |
UroGen Long Term Debt Regression Statistics
| Arithmetic Mean | 57,809,436 | |
| Geometric Mean | 13,842,497 | |
| Coefficient Of Variation | 89.71 | |
| Mean Deviation | 49,477,757 | |
| Median | 97,537,000 | |
| Standard Deviation | 51,862,258 | |
| Sample Variance | 2689.7T | |
| Range | 118.1M | |
| R-Value | 0.89 | |
| Mean Square Error | 580T | |
| R-Squared | 0.80 | |
| Slope | 9,735,493 | |
| Total Sum of Squares | 40345.4T |
UroGen Long Term Debt History
Other Fundumenentals of UroGen Pharma
About UroGen Pharma Financial Statements
UroGen Pharma investors utilize fundamental indicators, such as Long Term Debt, to predict how UroGen Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Long Term Debt | 113.3 M | 119 M | |
| Long Term Debt Total | 4.2 M | 2.5 M | |
| Short and Long Term Debt Total | 115.2 M | 121 M | |
| Long Term Debt To Capitalization | 3.40 | 3.23 |
Check out the analysis of UroGen Pharma Correlation against competitors. To learn how to invest in UroGen Stock, please use our How to Invest in UroGen Pharma guide.You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of UroGen Pharma. If investors know UroGen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about UroGen Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.02) | Revenue Per Share | Quarterly Revenue Growth 0.209 | Return On Assets | Return On Equity |
The market value of UroGen Pharma is measured differently than its book value, which is the value of UroGen that is recorded on the company's balance sheet. Investors also form their own opinion of UroGen Pharma's value that differs from its market value or its book value, called intrinsic value, which is UroGen Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because UroGen Pharma's market value can be influenced by many factors that don't directly affect UroGen Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between UroGen Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if UroGen Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, UroGen Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.